Outcomes of second-line oral antidiabetic drugs in persons with young-onset type 2 diabetes

doi:10.1016/j.diabres.2021.108928

中山醫學大學機構典藏 CSMUIR > 中山醫學大學研究成果 > 期刊論文 > Item 310902500/24076

Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/24076

Title:	Outcomes of second-line oral antidiabetic drugs in persons with young-onset type 2 diabetes
Authors:	Yen, FS;Wei, JCC;Liu, JS;Hsu, CC;Hwu, CM
Keywords:	Young-onset diabetes;All-cause hospitalization;Non-infection hospitalization;All-cause mortality;Dipeptidyl peptidase-4 inhibitors
Date:	2021
Issue Date:	2022-08-05T09:47:26Z (UTC)
Publisher:	ELSEVIER IRELAND LTD
ISSN:	0168-8227
Abstract:	Aim: People with young-onset diabetes (YOD) exhibit a higher risk of morbidity and mortality than those with late-onset diabetes. Few studies have explored the preferred management of diabetes in such patients. We compared the risks of hospitalization and mortality among people with YOD to whom second-line oral antidiabetic drugs (OADs) were administered. Methods: 7257 people taking second-line OADs after initial metformin therapy were enrolled during 2009-2014. Using add-on sulfonylureas (SUs) as a reference, the multivariable Cox regression model was used to compare the hospitalization and mortality risks among 5 categories of second-line OADs: alpha-glucosidase inhibitors, meglitinide, dipeptidyl peptidase-4 (DPP-4) inhibitors, SUs, and thiazolidinediones. Results: After baseline characteristics, comorbidities, duration of diabetes, and drug use were controlled, the adjusted hazard ratios and 95% confidence interval for all-cause, cardiovascular, and non-infection hospitalization and all-cause mortality for metformin plus DPP-4 inhibitors were 0.62 (0.52-0.73), 0.49 (0.29-0.85), 0.64 (0.54-0.76), and 0.50 (0.27-0.92), respectively, when compared with the data for metformin plus SUs. Conclusions: Among people with YOD, taking add-on DPP-4 inhibitors was associated with lower risks of all-cause hospitalization and mortality than taking add-on SUs. DPP-4 inhibitors thus seem to be a suitable second-line OAD for such patients. (c) 2021 Elsevier B.V. All rights reserved.
URI:	http://dx.doi.org/10.1016/j.diabres.2021.108928 https://www.webofscience.com/wos/woscc/full-record/WOS:000680513200006 https://ir.csmu.edu.tw:8080/handle/310902500/24076
Relation:	DIABETES RESEARCH AND CLINICAL PRACTICE ,2021,v177
Appears in Collections:	[中山醫學大學研究成果] 期刊論文

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	230	View/Open

Loading...